We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Show more
A Massachusetts-based biotech company is stealing the mid-week spotlight so far during Wednesday’s session after the company announced Q3 2024 GAAP EPS of $(0.09), which To read the full...
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET...
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.43 | -20.9756097561 | 2.05 | 2.12 | 1.44 | 2006624 | 1.69110567 | CS |
4 | -0.37 | -18.5929648241 | 1.99 | 2.8292 | 1.44 | 1332213 | 2.06732557 | CS |
12 | -0.28 | -14.7368421053 | 1.9 | 2.83 | 1.44 | 1134513 | 2.1528666 | CS |
26 | -0.5 | -23.5849056604 | 2.12 | 2.83 | 1.22 | 1123405 | 1.96569226 | CS |
52 | -0.4 | -19.801980198 | 2.02 | 6.2801 | 1.22 | 1566759 | 3.02895308 | CS |
156 | -4.64 | -74.1214057508 | 6.26 | 9.62 | 0.8014 | 2078341 | 3.43076083 | CS |
260 | -3.73 | -69.7196261682 | 5.35 | 29.09 | 0.8014 | 1624670 | 6.36578605 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions